Skip to content

Evaluation of an Opioid Decrease Strategy in Chronic

Evaluation of an Opioid Decrease Strategy in Chronic Pain Patients at the Pain Assessment and Treatment Center in Montpellier: Prospective Study Over 6 Months.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04424459
Acronym
EODSCPP
Enrollment
8
Registered
2020-06-11
Start date
2019-10-01
Completion date
2020-07-30
Last updated
2020-12-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain

Keywords

Opioid analgesics, Opioid use disorders, Prescription drug abuse, treatments Prevention Identification

Brief summary

Increase in the consumption of analgesics observed in many countries with a mediatic crisis resulting in an increasingly frequent wish of patients to wean themselves from opiates. A recent update (B. Rolland 2017) suggests that upon initiation of an opioid analgesic treatment, the patient should be informed of the risk of opioid dependence and misuse. There is no clearly validated decay scheme in the event of dependence in patients with Chronic Non-Cancer Pain. Hypotheses: * Possibility of a rapid decrease in opioid analgesic treatments at DCNC sensitized to the risk of DOP and MOP. (Protocol implemented: Multidisciplinary assessment, workshops and information sheet on chronic pain, treatments and risk of DOP, pharmacological and nonpharmacological adaptation) * Highlight the need for additional information from patients and prescribers on the risk of DOP and MOP in DCNC.

Detailed description

Main objective: Check if the rapid to semi-rapid regimen (- 25 to -60% dosage in 5 days of HDS) of opioid analgesics, without the use of methadone or buprenorphine agonists, in the case of DCNC at the CETD in Montpellier is efficient in the medium term (6 months). Secondary objective: * With our inclusion questionnaire we wanted to check if the patients had been made aware of the risk of opiate dependence and misuse. * Detect the conditions of prescriptions that can promote the misuse of opiates. * Evaluating the different components of residual pain at 6 months (type, intensity, anxiety component and depression, function).

Interventions

DRUGopioid withdrawal

The data retrieved from the patient will be encrypted and there will also be written data or written in binary form. They will be used to create an Excel table which allows me to list the data on D1 then on M + 3 then on M + 6 in order to evaluate the evolution of these data over a time interval of 6 months and this is which will be used as support in my thesis in pharmacy.

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* chronic pain patient * major * supported at CETD

Exclusion criteria

-patient with physical and mental incapacity to participate in the study

Design outcomes

Primary

MeasureTime frameDescription
Change of the dosage of opioid and co-analgesic treatments3 months and 6 monthsChange of the dosage of opioid and co-analgesic treatments

Secondary

MeasureTime frameDescription
Measuring quality of lifeInclusion, 3 and 6 monthsinterview with the patient

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026